The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2019 | Further progression for CAR T-cell therapy?
Paolo Strati, MD, of the University of Texas MD Anderson Cancer enter, Houston, RX, discusses the need for larger data sets and further goals to improve CAR T-cell therapy. Dr Strati also discusses the need for further biological understanding and potential studies to explain the unexpected relationship between platelet counts & NK cells observed here. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
